WO2015192854A3 - Methods and tools for predicting steatohepatitis - Google Patents

Methods and tools for predicting steatohepatitis Download PDF

Info

Publication number
WO2015192854A3
WO2015192854A3 PCT/DK2015/050163 DK2015050163W WO2015192854A3 WO 2015192854 A3 WO2015192854 A3 WO 2015192854A3 DK 2015050163 W DK2015050163 W DK 2015050163W WO 2015192854 A3 WO2015192854 A3 WO 2015192854A3
Authority
WO
WIPO (PCT)
Prior art keywords
nash
methods
scd163
tools
steatohepatitis
Prior art date
Application number
PCT/DK2015/050163
Other languages
French (fr)
Other versions
WO2015192854A2 (en
Inventor
Henning GRØNBÆK
Konstantin KAZANKOV
Holger Jon MØLLER
Jacob George
Original Assignee
Aarhus Universitet
Region Midtjylland
The University Of Sydney
Westmead Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet, Region Midtjylland, The University Of Sydney, Westmead Hospital filed Critical Aarhus Universitet
Publication of WO2015192854A2 publication Critical patent/WO2015192854A2/en
Publication of WO2015192854A3 publication Critical patent/WO2015192854A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Abstract

The present application relates to methods and tools for assessing disease progression of non-alcoholic steatohepatitis (NASH). The methods are based on the demonstration that sCD163 levels correlate significantly with histological diagnosis of NASH, and that consequently the use of sCD163 serum level can be used to improve existing NASH diagnosis. In other aspects there is provided novel non-invasive NASH scores based on assessment of a few easily detectable markers, including sCD163, and optionally ALT, and the presence of diabetes.
PCT/DK2015/050163 2014-06-16 2015-06-12 Methods and tools for predicting steatohepatitis WO2015192854A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201400314 2014-06-16
DKPA201400314 2014-06-16
DKPA201400643 2014-11-04
DKPA201400643 2014-11-04

Publications (2)

Publication Number Publication Date
WO2015192854A2 WO2015192854A2 (en) 2015-12-23
WO2015192854A3 true WO2015192854A3 (en) 2016-02-18

Family

ID=53773130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2015/050163 WO2015192854A2 (en) 2014-06-16 2015-06-12 Methods and tools for predicting steatohepatitis

Country Status (1)

Country Link
WO (1) WO2015192854A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109072302B (en) * 2016-03-30 2024-01-16 基恩菲特公司 Non-invasive diagnosis of non-alcoholic steatohepatitis
WO2018154140A1 (en) 2017-02-27 2018-08-30 Université d'Angers Non-invasive diagnosis of fibrotic non-alcoholic steatohepatitis
AU2018253885B2 (en) * 2017-04-18 2024-04-11 Genfit Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
CN108254455A (en) * 2017-12-07 2018-07-06 山东省药学科学院 A kind of method of the high effective liquid chromatography for measuring roflumilast in relation to substance
CN113160983A (en) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 Metabolism-related fatty liver disease clinical prediction model

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014049131A1 (en) * 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
WO2011044904A2 (en) 2009-10-12 2011-04-21 Aarhus Universitet Method of prognosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014049131A1 (en) * 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. KAZANKOV ET AL: "P824 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE", JOURNAL OF HEPATOLOGY, vol. 60, no. 1, 1 April 2014 (2014-04-01), pages S345 - S346, XP055215668, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(14)60985-5 *
TOLMAN KEITH G ET AL: "Treatment of non-alcoholic fatty liver disease", THERAPEUTICS AND CLINICAL RISK MANAGEMENT, DOVE MEDICAL PRESS LTD, NZ, vol. 3, no. 6, 1 December 2007 (2007-12-01), pages 1153 - 1163, XP002631826, ISSN: 1176-6336 *

Also Published As

Publication number Publication date
WO2015192854A2 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
WO2015192854A3 (en) Methods and tools for predicting steatohepatitis
WO2016191737A3 (en) Systems and methods for proactively identifying and surfacing relevant content on a touch-sensitive device
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
EP2913689A3 (en) Proximity detection of candidate companion display device in same room as primary display using WI-FI or bluetooth signal strength
MX2018009304A (en) Diagnostic and prognostic methods for cardiovascular diseases and events.
WO2015176066A3 (en) Lpa-associated protein and rna expression
WO2014186728A3 (en) Methods for diagnosing and treating inflammatory bowel disease
MX2021012347A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
WO2015092046A3 (en) Prostate cancer biomarkers
EP4067507A3 (en) Pna probes, kits and methods for detecting genotypes of human papillomavirus
WO2015185672A3 (en) New markers for the assessment of an increased risk for mortality
BR112015019567A2 (en) markers associated with wnt inhibitors
Gardiner First-trimester fetal echocardiography: routine practice or research tool?
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
WO2014166303A3 (en) Use of multiomic signature to predict diabetes
RU2016135755A (en) CONTACT AREA DIFFUSION COEFFICIENT FOR QUANTITATIVE DETERMINATION OF LIQUID FAT CONTENT
WO2015032414A3 (en) Methods and tools for predicting liver fibrosis
WO2014143794A3 (en) Diagnostic and prognostic marker for prostate cancer
EP2793102A3 (en) Information processing device
WO2015134631A8 (en) Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy
WO2015092444A3 (en) Biomarkers
SG10201901836PA (en) Test strip assembly
WO2015138026A8 (en) Method and device for detecting and assessing reactive hyperemia using segmental plethysmography
EP2778230A3 (en) Compositions and methods for performing assays

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15745142

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 15745142

Country of ref document: EP

Kind code of ref document: A2